Plasma Concentration of Biological Markers in Placenta Accreta Spectrum
Status
Conditions
Details and patient eligibility
About
The purpose of this exploratory study is to determine how well maternal serum biomarkers and placental micro-particles (MP) correlate with placenta accreta spectrum (PAS) at the time of cesarean delivery in women with suspected PAS compared to women without PAS. Our aim is to determine if women with PAS have a unique MP and protein signature at the time of delivery compared with women without PAS.
Full description
Maternal blood samples will be taken at various points during the intrapartum period. A healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. The primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers The knowledge gained from this study has the potential to develop a diagnostic test for PAS with the ability to improve management and outcomes for mother and baby through earlier diagnosis.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Age 18 - to 45-years old, inclusive
- Suspected or confirmed PAS or phenotypically matched controls
- Delivery by cesarean section
- Gestational age greater than 28 weeks
- Singleton pregnancy
Exclusion criteria
- Intrauterine fetal demise,
- Severe fetal anomalies (infant not expected to survive)
- Emergent cesarean delivery
Trial design
19 participants in 2 patient groups
Trial contacts and locations
Loading...
Central trial contact
Nadir Sharawi, MD
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal